Olmesartan medoxomil/amlodipine/hydrochlorothiazide 20 mg/5 mg/12.5 mg fixed-dose combination in hypertension: a profile of its use
AbstractThe triple-component fixed-dose combination of olmesartan medoxomil (OLM)/amlodipine (AML)/hydrochlorothiazide (HCT) is a rational choice for patients who require treatment with three or more antihypertensives. The three drugs in the FDC have complementary mechanisms of action, with OLM, AML and HCT being an angiotensin II receptor blocker, calcium channel blocker and diuretic, respectively. Once-daily OLM/AML/HCT 20 mg/5 mg/12.5 mg reduced systolic and diastolic blood pressure, thereby enabling patients to achieve blood pressure goals, and was generally well tolerated in clinical trials. Moreover, the use of a fixed-dose combination comprising three antihypertensive components reduces pill burden, which may improve patient adherence to treatment and, ultimately, clinical outcomes.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research
More News: Benicar | Calcium | Clinical Trials | Drugs & Pharmacology | Hydrochlorothiazide | Hypertension | Norvasc